Natera, Inc. and Alliance Foundation Trials, LLC Announces Initial Translational Research Results from the International Randomized Phase III PALLAS Study

Natera, Inc. and Alliance Foundation Trials, LLC announced initial results from the Phase III PALLAS study at SABCS. The study shows that MRD status, measured by Signatera, is a prognostic biomarker for recurrence risk in stage II-III HR+/HER2- breast cancer. Findings support integrating MRD testing into post-surgical risk assessment for personalized management. Key results include high DRFI for MRD-negative patients, indicating low recurrence risk. Palbociclib is not approved in EBC.